Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday
04:18pm, Tuesday, 18'th Jan 2022
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 05'th Jan 2022
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
04:48pm, Friday, 03'rd Dec 2021
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
07:45am, Wednesday, 13'th Oct 2021
- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 -
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
10:21am, Friday, 01'st Oct 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program. DMD is a r
- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model -
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
07:30am, Tuesday, 28'th Sep 2021
- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne's DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leadi
Dyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference
07:30am, Monday, 27'th Sep 2021
WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
- New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction -
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
07:30am, Thursday, 05'th Aug 2021
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line -
Dyne Therapeutics Announces Chief Scientific Officer Transition
04:05pm, Wednesday, 02'nd Jun 2021
- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts -
Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies
02:44pm, Friday, 14'th May 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -
Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, followin
